Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Alla, Markovich"'
Autor:
Alla Markovich, V. V Delektorskaya, Nadezhda Fedorovna Orel, Kristina V. Orlova, Lev V. Demidov, T.T. Kondratieva, Somasundaram Subramanian, Yana V Vishnevskaya
Publikováno v:
Journal of the European Academy of Dermatology and Venereology. 32:e236-e237
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47a9c58670a9efabc3540a521cfdf30e
https://doi.org/10.1111/jdv.14769
https://doi.org/10.1111/jdv.14769
Autor:
Alla, Markovich, Orel, Nadezhda, Margaryan, Armen, Kuzminov, Alexander, Emelyanova, Galina, Odintsova, Anastasia, Gorbunova, Vera
Publikováno v:
In Annals of Oncology June 2017 28 Supplement 3:iii66-iii66
Autor:
A. Odintsova, Alla Markovich, G. Emelianova, Nadezhda Fedorovna Orel, A. Mnatsakanyan, Vera Gorbunova, A. Kuzminov
Publikováno v:
Annals of Oncology. 25:iv401
Aim: To evaluate efficacy and safety of everolimus combined with long-acting octreotide in heavily pretreated patients with NETs. To determine predictive factors for everolimus efficacy. Methods: 33 pts with progressive well differentiated NETs (G1,G
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b9ea598eba03228016c3a0ef8584151e
https://doi.org/10.1093/annonc/mdu345.18
https://doi.org/10.1093/annonc/mdu345.18
Autor:
Gorbunova Vera, Odintsova Anastasia, Kuzminov Alexander, Emelyanova Galina, Margaryan Armen, Alla Markovich, Orel Nadezhda
Publikováno v:
Annals of Oncology. 25:ii60
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85ab8085605c33cf213e1de49908cae5
https://doi.org/10.1093/annonc/mdu165.149
https://doi.org/10.1093/annonc/mdu165.149
Autor:
E. A. Moskvina, D. R. Naskhletashvili, Ali Bekyashev, Alla Markovich, Vera Gorbunova, Vladislav Karahan, Vladimir Aloshin, Sevyan Nadejda, S. V. Medvedev, Zoya Michina, M. B. Bychkov
Publikováno v:
Journal of Clinical Oncology. 32:e13027-e13027
e13027 Background: Metastases in the brain is a rare complication of the tumor process in patients (pts) with ovarian cancer. About 1–2% of all pts with ovarian cancer develop BM, leading to a poor prognosis and a median survival of 18 years with E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c0b4a406f11cd874d44ee25bca4a432d
https://doi.org/10.1200/jco.2014.32.15_suppl.e13027
https://doi.org/10.1200/jco.2014.32.15_suppl.e13027
Autor:
Alla Markovich, S. V. Medvedev, Vladimir Aloshin, Vladislav Karahan, Ali Bekyashev, Vera Gorbunova, M. B. Bychkov, Evgeny Prozorenko, Zoya Michina, D. R. Naskhletashvili
Publikováno v:
Journal of Clinical Oncology. 31:e15546-e15546
e15546 Background: About 2–11% of all patients (pts) with RCC develop BM, leading to a poor prognosis and a median survival of 18 years with ECOG performanse status (PS) of 0–2. From June 2009 to January 2013, 11 pts with RCC and BM were enrolled
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::14176641c3f0c9a50b7f1db12373b6e2
https://doi.org/10.1200/jco.2013.31.15_suppl.e15546
https://doi.org/10.1200/jco.2013.31.15_suppl.e15546
Publikováno v:
Annals of Oncology. 23:iv71
Introduction To evaluate the effectiveness of XELOX in patients with disseminated neuroendocrine tumors (NET) of gastrointestinal tract. Methods 50 patients with morphologically verified NET of gastrointestinal tract,17 (34%) men and 33 (66%) women a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::710a3393d25e64e42f7ee40a7eb091e6
https://doi.org/10.1016/s0923-7534(20)30059-4
https://doi.org/10.1016/s0923-7534(20)30059-4
Publikováno v:
Lung Cancer. 41:S100
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d9f48a03c9de4d4450b9d1dba881b667
https://doi.org/10.1016/s0169-5002(03)92007-1
https://doi.org/10.1016/s0169-5002(03)92007-1